ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Proteinuria"

  • 2019 American Transplant Congress

    The Implications of Donor Proteinuria in Deceased Donor Kidney Transplantation

    A. Vinson, T. Keough-Ryan, K. West, K. Tennankore

    Dalhousie University, Halifax, NS, Canada

    *Purpose: The implications of pre-terminal donor urinalysis findings on post-transplant kidney graft survival has not been previously explored. An abnormal donor urinalysis may reflect donor…
  • 2019 American Transplant Congress

    Impact Of Rituximab And Maintenance Steroid In The Recurrence Of Focal Segmental Glomerulosclerosis

    L. A. Mendez Castaner

    Transplant, Miami Transplant Institute-University of Miami, Miami, FL

    *Purpose: Recurrence of focal segmental glomerulosclerosis (FSGS) has been reported between 20-80% with up to 60% of graft loss. Rituximab has demonstrated to be effective…
  • 2019 American Transplant Congress

    Renal Pathological Findings in Living Kidney Donor Candidates with Minimal Urinary Abnormalities

    H. Ahmed1, C. Drachenberg2, R. Ugarte1, N. Costa1, C. Cangro1, R. N. Barth3, M. Weir1, A. Harirain1

    1Medicine-Nephrology, University of Maryland Medical Center, Baltimore, MD, 2Pathology, University of Maryland Medical Center, Baltimore, MD, 3Surgery, University of Maryland Medical Center, Baltimore, MD

    *Purpose: With the increasing number of ESRD patients requiring transplantation and stagnant number of deceased-donor organs available, minimizing the exclusion of living donor candidates with…
  • 2019 American Transplant Congress

    Use of Opioids and NSAIDs in Living Kidney Donors: Clinical Correlates and Early Outcomes

    K. Lentine1, L. Vest1, Z. Zhang1, F. Koraishy1, M. Schnitzler1, A. Garg2, D. Axelrod3, B. Kasiske4, G. Hess5, A. Naik6, D. Segev7, M. Henderson7, A. Massie7, N. Lamm8

    1Saint Louis Univ, St. Louis, MO, 2Western Univ, London, ON, Canada, 3Univ of Iowa, Iowa City, IA, 4SRTR, Minneapolis, MN, 5Univ of Pennsylvania, Philadelphia, PA, 6Univ of Michigan, Ann Arbor, MI, 7Johns Hopkins, Baltimore, MD, 8Univ Alberta, Edmonton, AB, Canada

    *Purpose: Data are limited regarding pain medication use in living kidney donors (LKD). Concerns relate to opioid use, and to non-steroidal anti-inflammatory (NSAID) use in…
  • 2019 American Transplant Congress

    An Interesting Case of Proteinuria in Living Kidney Donor

    A. Yadav, W. Maley, P. Singh

    Thomas Jefferson University, Philadelphia, PA

    *Purpose: Evaluation for proteinuria is vital to assess suitability for live kidney donation. Living unrelated donor with orthostatic proteinuria was evaluated. This case highlights importance…
  • 2019 American Transplant Congress

    Sex Specific Regulation of Podocyte-Specific Genes and Proteins Determines Glomerular Response to mTOR Inhibition

    A. Kusch1, O. AlDiab2, D. Gürgen2, C. Sünkel3, F. Grahammer4, M. Rinschen5, T. Huber4, N. Rajewsky3, D. Dragun2

    1Medizinische Klinik m. S. Nephrologie und Internistische Intensivmedizin, Charité Universitätsmedizin Berlin, Berlin, Germany, 2Medizinische Klinik m. S. Nephrologie und internistische Intensivmedizin, Charité Universitätsmedizin Berlin, Berlin, Germany, 3Max-Delbrück Center for Molecular Medicine, Berlin, Germany, 4III. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg - Eppendorf, Hamburg, Germany, 5CECAD Research Center, Universitätsklinikum Köln, Köln, Germany

    *Purpose: mTOR inhibitors are increasingly used in transplantation with high interindividual variation in proteinuric responses. Although males have higher prevalence and faster progression of glomerular…
  • 2019 American Transplant Congress

    Shroom3 Regulates Glomerular Hypertrophy after Uninephrectomy via mTOR

    K. Banu, F. Garzon, C. Wei, Z. Yi, W. Zhang, C. He, B. Murphy, M. C. Menon

    Mount Sinai School of Medicine, New York, NY

    *Purpose: A Shroom3 intronic risk locus & Shroom3 protein have been associated with increased fibrosis but reduced albuminuria in recipients of allografts with the risk…
  • 2019 American Transplant Congress

    Significance of Histopathologic Features for Predicting Progression in Patients with Transplant Glomerulopathy

    X. Li, J. Chen, D. Cheng, R. Wang, W. Wang, M. Zhang, F. Xu, J. Wen, Z. Tang

    National Clinical Research Center of Kidney Diseases, Nanjing, China

    *Purpose: Transplant glomerulopathy (TG) represents a major cause of long-term allograft failure and is the leading cause of overall post-transplant proteinuria. We aimed to determine…
  • 2019 American Transplant Congress

    Assessment of Proteinuria Reported as Adverse Events in De Novo Renal Transplant Recipients Receiving an Everolimus-Based Regimen: 24-Month Results from TRANSFORM

    C. Legendre1, S. Berger1, F. Oppenheimer1, A. Wiseman1, S. Steinberg1, O. Viklicky1, G. Russ1, R. Danguilan1, N. Basic-Jukic1, E. Mor1, P. Narvekar2, M. P. Hernandez Gutierrez2, P. Bernhardt2, C. Sommerer1

    1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland

    *Purpose: mTOR inhibitors (eg, everolimus [EVR]), are thought to increase the risk of post-transplant (Tx) proteinuria (PU). Here, we assess PU onset and outcomes in…
  • 2018 American Transplant Congress

    Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study

    F. Oppenheimer,1 C. Legendre,1 J. Cruzado,1 G. Russ,1 O. Viklicky,1 R. Oberbauer,1 V. Garcia,1 O. Witzke,1 D. Kuypers,1 R. Danguilan,1 P. Bernhardt,2 C. Sommerer.1

    1TRANSFORM Study Group, Barcelona, Spain; 2Novartis Pharma AG, Basel, Switzerland.

    Purpose: TRANSFORM (NCT01950819) is the largest study conducted in de novo kidney transplant recipients (KTxRs) to evaluate the benefit of everolimus with reduced-dose calcineurin inhibitor…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences